Casamba Revenue and Competitors
Estimated Revenue & Valuation
- Casamba's estimated annual revenue is currently $22.6M per year.
- Casamba's estimated revenue per employee is $159,500
Employee Data
- Casamba has 142 Employees.
Casamba's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Product Manager Home Health Solutions | Reveal Email/Phone |
2 | President | Reveal Email/Phone |
3 | QA Engineer | Reveal Email/Phone |
4 | Software Specialist | Reveal Email/Phone |
5 | Clinical Application Specialist | Reveal Email/Phone |
Casamba Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $3.6M | 31 | N/A | N/A | N/A |
#2 | $9.1M | 72 | -18% | $58.2M | N/A |
#3 | $0.4M | 6 | N/A | N/A | N/A |
#4 | $0.3M | 4 | N/A | N/A | N/A |
#5 | $2M | 20 | N/A | N/A | N/A |
#6 | $1.9M | 12 | N/A | N/A | N/A |
#7 | $3.5M | 31 | N/A | N/A | N/A |
#8 | $0.3M | 4 | N/A | N/A | N/A |
#9 | $1.6M | 10 | N/A | N/A | N/A |
#10 | $0.6M | 4 | N/A | N/A | N/A |
#11 | $5.6M | 48 | -9% | N/A | N/A |
#12 | $10.8M | 41 | 71% | $25M | N/A |
#13 | $4.3M | 40 | -18% | $26.2M | N/A |
#14 | $0.4M | 6 | N/A | N/A | N/A |
#15 | $3.9M | 35 | N/A | N/A | N/A |
#16 | $1M | 11 | N/A | N/A | N/A |
#17 | $35.4M | 108 | 74% | N/A | N/A |
#18 | $4.2M | 22 | N/A | N/A | N/A |
#19 | $0.3M | 4 | N/A | N/A | N/A |
#20 | $2.4M | 15 | N/A | N/A | N/A |
What Is Casamba?
N/A
Total Funding
142
Number of Employees
$22.6M
Revenue (est)
N/A
Employee Growth %
N/A
Valuation
N/A
Accelerator
Casamba News
2022-04-17 - Physical Therapy Software Market Size, Scope And Forecast ...
... PT Practice Pro, TherapySync, Net Health Therapy (formerly ReDoc powered by xfit), PT Wired, Casamba Clinic, PTlive, Phydeo, OptimisPT.
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $36.6M | 146 | 22% | N/A |
#2 | $45.1M | 152 | 0% | N/A |
#3 | $32.6M | 168 | -6% | $353M |
#4 | $46.3M | 175 | 4% | $8.2M |
#5 | $69.8M | 235 | 4% | N/A |
